China Pharma Inc. (CPHI)
AMEX: CPHI
· Real-Time Price · USD
1.46
0.00 (0.00%)
At close: Aug 15, 2025, 2:15 PM
China Pharma Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -4.57M | -4.74M | -4.74M | -4.4M | -3.56M | -3.08M | -3.11M | -3.12M | -3.42M | -3.97M | -3.69M | -3.73M | -3.66M | -3.4M | -3.63M | -3.81M | -2.97M |
Depreciation & Amortization | 2.21M | 2.62M | 2.87M | 2.85M | 2.81M | 2.75M | 2.7M | 2.68M | 2.67M | 2.7M | 2.77M | 3.08M | 3.1M | 3.09M | 3.08M | 2.78M | 2.72M |
Stock-Based Compensation | n/a | n/a | n/a | n/a | n/a | n/a | 78.27K | 78.27K | 78.27K | 78.27K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Working Capital | 820.87K | 520.23K | 146.87K | 646.82K | 593.34K | 246.86K | 615.42K | 196.64K | 186.02K | 703.52K | 511.21K | 456.41K | 269.4K | 803.35K | 729.31K | 918.59K | -394.4K |
Other Non-Cash Items | 544.3K | 456.44K | 476.98K | 429.2K | 163.86K | 29.63K | 11.26K | 353.69K | 310.87K | 325.54K | 186.67K | -108.49K | -31.25K | 10.03K | 231.91K | 198.9K | 130.86K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 1.87M | 1.2M | 674.18K | 1.45M | 770.68K | -404.15K | 231.25K | -448.02K | -215.59K | 878.34K | -41.98K | -1.11M | -260.66K | 51.79K | 600.82K | 1.35M | 43.59K |
Operating Cash Flow | 60.97K | -466.36K | -727.16K | 327.08K | 183.37K | -699.69K | -92.77K | -880.93K | -998.32K | -409.55K | -1.19M | -1.86M | -852.36K | -249.84K | 283.14K | 509.6K | -75.02K |
Capital Expenditures | -372.68K | -291.72K | -23.39K | -32.61K | -4.53K | -4.53K | -149.41K | -401.96K | -577.25K | -578.65K | -436.29K | -599.72K | -439.45K | -438.06K | -198.43K | -41.88K | -519.51K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -275.95K | -253.31K | n/a | -67.45K | -62.95K | -6.99K | 169.69K | 237.15K | 232.65K | 176.68K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | -372.68K | -291.72K | -23.39K | -100.07K | -67.48K | -11.52K | 20.28K | -164.82K | -344.61K | -401.96K | -436.29K | -599.72K | -439.45K | -438.06K | -198.43K | -41.88K | -519.51K |
Debt Repayment | -49.47K | 27.35K | 50.93K | -432.32K | -445.09K | 73.14K | -629.3K | -124.5K | -975.99K | -1.77M | 3.52M | 3.07M | 4.47M | 4.6M | -32.32K | -841.1K | 586.01K |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -69 | n/a | n/a | n/a | 6.86K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Financial Cash Flow | -49.54K | 27.35K | 50.93K | -432.32K | -438.24K | 73.14K | -629.3K | -124.5K | -975.99K | -1.77M | 3.52M | 3.07M | 4.47M | 4.6M | -32.32K | -841.1K | 586.01K |
Net Cash Flow | -426.19K | -796.96K | -651.18K | -162.57K | -328.07K | -606.13K | -716.43K | -1.34M | -2.55M | -2.83M | 1.63M | 490.09K | 3.18M | 3.9M | 112.22K | -281.67K | 57.56K |
Free Cash Flow | -311.71K | -758.08K | -750.55K | 287.48K | 171.85K | -711.2K | -249.17K | -1.28M | -1.58M | -988.19K | -1.63M | -2.46M | -1.29M | -687.89K | 84.71K | 467.72K | -594.53K |